Evidence map›Paper›PMID 21161613›Full record

ReviewMolecular neurobiology2011

The role of PML in the nervous system.

Paolo Salomoni, Joanne Betts-Henderson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Topoisomerase II and leukemia.Annals of the New York Academy of Sciences · 2014
    Review
  4. Review
  5. Review
  6. Article
  7. On Rita Levi-Montalcini.Molecular neurobiology · 2013
    Article
  8. Tumor suppressive pathways in the control of neurogenesis.Cellular and molecular life sciences : CMLS · 2013
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Rita's 102!!Molecular neurobiology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Paolo SalomoniSamantha Dickson Brain Cancer Unit, UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. p.salomoni@ucl.ac.uk
Joanne Betts-Henderson
CRUK Lung Cancer Centre of Excellence · GB

Funding

Medical Research Council MC_U132670601Wellcome Trust
6 · The paper itself

Abstract

The promyeloctic leukemia protein PML is a tumor suppressor that was originally identified due to its involvement in the (15;17) translocation of acute promyelocytic leukemia. While the majority of early research has focused upon the role of PML in the pathogenesis of leukemia, more recent evidence has identified important roles for PML in tissues outside the hemopoietic system, including the central nervous system (CNS). Here, we review recent literature on the role of PML in the CNS, with particular focus on the processes of neurodevelopment and neurodegeneration, and propose new lines of investigation.

Indexed as

AnimalsHumansNervous SystemNeural Stem CellsTumor Suppressor ProteinsTumor Suppressor Proteins

Identifiers

PMID21161613
OpenAlexW1996946868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.